Rikke B. Holmgaard

发表

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Xiaohong Xu, Philip W. Iversen, David K. Clawson, 2017, Oncotarget.

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity

J. Wolchok, P. Sharma, J. Allison, 2017, Nature Communications.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

J. Wolchok, J. Allison, P. Palese, 2014, Science Translational Medicine.

Tumor-Expressed IDO Rec ruits and Activates MDSCs in a Treg-Dependent Manner Graphical Abstract Highlights

J. Wolchok, D. Munn, J. Allison, 2015 .

The PTEN pathway in Tregs functions as a critical driver of the immunosuppressive tumor microenvironment and tolerance to apoptotic cells

Loise M. Francisco, J. Wolchok, D. Munn, 2015, Journal of Immunotherapy for Cancer.

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

J. Wolchok, D. Munn, J. Allison, 2013, The Journal of experimental medicine.

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors

J. Wolchok, A. Lesokhin, T. Merghoub, 2016, EBioMedicine.

The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.

J. Wolchok, T. Merghoub, Billel Gasmi, 2015, Advances in cancer research.

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.

J. Wolchok, D. Munn, J. Allison, 2015, Cell reports.

The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment

Loise M. Francisco, J. Wolchok, D. Munn, 2015, Science Advances.

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

P. Iversen, M. Kalos, G. Plowman, 2018, Journal of Immunotherapy for Cancer.

Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy

David R. Jones, T. Doman, J. Wolchok, 2016, Oncoimmunology.

FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety

D. Witcher, Jinsam You, A. Koester, 2018, mAbs.

Association of a functional Indoleamine 2,3-dioxygenase 2 genotype with specific immune responses

T. Klausen, P. Straten, Rikke B. Holmgaard, 2012, Oncoimmunology.

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4

J. Wolchok, D. Munn, J. Allison, 2013, Journal of Immunotherapy for Cancer.

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.

J. Wolchok, D. Munn, J. Allison, 2015, Cell reports.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.